UOC
NVCR icon

UBS O'Connor’s NovoCure NVCR Stock Holding History

UBS O'Connor’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-100,000
Closed -$120K – 609
2024
Q1 		$120K Buy
+100,000
New +$1.47M ﹤0.01% 416
2023
Q4 		– Sell
-25,000
Closed -$19.4K – 577
2023
Q3 		$19.4K Buy
25,000
+3,000
+14% +$86.5K ﹤0.01% 512
2023
Q2 		$101K Buy
+22,000
New +$1.37M ﹤0.01% 493

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

UBS O'Connor's NVCR Position: Q2 2024 in Review

UBS O'Connor sold out of NovoCure (NVCR) in Q2 2024, closing a stake of 22,782 shares — an estimated $356K sold.

UBS O'Connor first reported a position in NVCR in Q1 2024 and held it in 1 quarter. The position peaked at $356K in Q1 2024. 236 funds tracked by Wall St. Rank hold NVCR as of Q2 2024.

  • UBS O'Connor reported no remaining NovoCure position as of Q2 2024 after selling out during the quarter.
  • UBS O'Connor sold 22,782 NovoCure shares in Q2 2024, an estimated $356K.
  • UBS O'Connor first reported a position in NovoCure in Q1 2024 and held it in 1 quarter.
  • UBS O'Connor's NovoCure position peaked at $356K in Q1 2024.
  • 236 funds tracked by Wall St. Rank held NovoCure as of Q2 2024.

Based on UBS O'Connor's 13F filing for Q2 2024, filed 14 Aug 2024.